PetCure Oncology, LLC, a company providing veterinary cancer treatment utilizing non-surgical stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT), announced that it has engaged Boustead Securities, LLC, for a Regulation D 506(c) offering and other capital markets services, including serving as underwriter for the company’s planned IPO.
July 17, 2019
· 3 min read